Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review

Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review

Ten percent of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations harbor uncommon variants. These mutations are mainly involved in lung adenocarcinomas but are rare in lung squamous cell carcinoma (LSCC). In 2018, the Food and Drug Administration-approved afat...

Full description

Bibliographic Details
Main Authors: Ruoyu Deng, Wen Zhang, Jialing Lv, Fang Wang, Yanqiong Chen, Chengqi Jiang, Yaling Guan, Chao Zhang
Format: Article
Language:English
Published: Elsevier 2024-08-01
Series:Heliyon
Subjects:
Afatinib
Squamous cell carcinoma
Non-small cell lung cancer
Epidermal growth factor receptor
Tyrosine kinase inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024113357

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024113357

Similar Items